Mixed Features in Patients With a Major Depressive Episode

Perugi, Giulio; Angst, Jules; Azorin, J.-M.; Bowden, Charles L.; Sn, Mosolov; Reis, João; Vieta, Eduard; Young, Allan H.

doi:10.4088/jcp.14m09092

Cited by 150 publications

(174 citation statements)

References 0 publications

Supporting

Mentioning

150

Contrasting

Unclassified

Order By: Relevance

“…[2][3][4][5][6][7][8][9][10][11][12] In MDD patients without mixed features, the presence of concurrent anxiety has been shown to reduce the likelihood of achieving an adequate antidepressant response. [19][20][21][22][23][24][25][26][27] We report here the results of a post-hoc analysis of a placebo-controlled, 6-week trial of MDD presenting with mixed features and anxiety which found that treatment with lurasidone significantly improved depressive symptoms in a subgroup of patients with moderate-to-severe anxiety at baseline.…”

Section: Lurasidone For Mdd With Mixed Features and Anxiety 241mentioning

confidence: 99%

“…1 The available evidence, largely from clinical study populations, suggests that major depressive disorder (MDD) with mixed features may occur in at least 25% of patients with major depression. [2][3][4][5][6][7][8][9][10][11][12] In patients with a diagnosis of MDD, the estimated lifetime prevalence of an anxiety disorder is greater than 35%. 13,14 The presence of comorbid anxiety in MDD has been found to be associated with greater illness severity, chronicity, and functional impairment.…”

Section: Introductionmentioning

confidence: 99%

“…[15][16][17][18] Preliminary research suggests that patients with a diagnosis of MDD with mixed features (subthreshold hypomania) may have rates of anxiety comorbidity in the range of 45-65%. 3,11 MDD with mixed features is also associated with higher severity of concurrent anxiety symptoms. [10][11][12] High levels of anxiety have frequently been reported to reduce the likelihood of achieving an adequate antidepressant response in patients with both unipolar MDD [19][20][21][22][23][24][25][26][27] and bipolar depression.…”

Section: Introductionmentioning

confidence: 99%

“…3,11 MDD with mixed features is also associated with higher severity of concurrent anxiety symptoms. [10][11][12] High levels of anxiety have frequently been reported to reduce the likelihood of achieving an adequate antidepressant response in patients with both unipolar MDD [19][20][21][22][23][24][25][26][27] and bipolar depression. [28][29][30] To our knowledge, no controlled trial to date has evaluated the potential impact of concurrent anxiety symptoms on response to treatment in patients presenting with MDD with mixed features.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Lurasidone for major depressive disorder with mixed features and anxiety: a post-hoc analysis of a randomized, placebo-controlled study

et al. 2017

View full text Add to dashboard Cite

Objective. The aim of this post-hoc analysis was to evaluate the efficacy of lurasidone in treating patients with major depressive disorder (MDD) with mixed features who present with mild and moderate-to-severe levels of anxiety.Methods. The data in this analysis were derived from a study of patients meeting the DSM-IV-TR criteria for unipolar MDD, with a Montgomery-Åsberg Depression Rating Scale (MADRS) total score ≥26, presenting with two or three protocol-defined manic symptoms, who were randomized to 6 weeks of double-blind treatment with either lurasidone 20-60 mg/day (n = 109) or placebo (n = 100). Anxiety severity was evaluated using the Hamilton Anxiety Rating Scale (HAM-A). To evaluate the effect of baseline anxiety on response to lurasidone, the following two anxiety groups were defined: mild anxiety (HAM-A ≤ 14) and moderate-to-severe anxiety (HAM-A ≥ 15). Change from baseline in MADRS total score was analyzed for each group using a mixed model for repeated measures.Results. Treatment with lurasidone was associated with a significant week 6 change versus placebo in MADRS total score for patients with both mild anxiety (-18.4 vs. -12.8, p < 0.01, effect size [ES] = 0.59) and moderate-to-severe anxiety (-22.0 vs. -13.0, p < 0.001, ES = 0.95). Treatment with lurasidone was associated with a significant week 6 change versus placebo in HAM-A total score for patients with both mild anxiety (-7.6 vs. -4.0, p < 0.01, ES = 0.62), and moderate-to-severe anxiety (-11.4 vs. -6.1, p < 0.0001, ES = 0.91).Conclusions. In this post-hoc analysis of an MDD with mixed features and anxiety population, treatment with lurasidone was associated with significant improvement in both depressive and anxiety symptoms in subgroups with mild and moderate-to-severe levels of anxiety at baseline.

show abstract

Section: Lurasidone For Mdd With Mixed Features and Anxiety 241mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Lurasidone for major depressive disorder with mixed features and anxiety: a post-hoc analysis of a randomized, placebo-controlled study

et al. 2017

View full text Add to dashboard Cite

show abstract

“…8 Prevalence estimates from clinical populations indicate that mixed features occur in at least 25% of patients with MDD. 11,14,[16][17][18][19][20][21][22] Irritability is not included as a criterion for mixed features in DSM-5, in part due to concerns regarding specificity. 8 Despite the prevalence and prognostic significance of irritability in MDD (with or without mixed features), few prospective studies have examined treatment response in this important clinical population.…”

Section: Introductionmentioning

confidence: 99%

Lurasidone for major depressive disorder with mixed features and irritability: a post-hoc analysis

et al. 2017

View full text Add to dashboard Cite

Objective. The aim of this post-hoc analysis was to evaluate the efficacy of lurasidone in treating major depressive disorder (MDD) with mixed features including irritability.Methods. The data in this analysis were derived from a study of patients meeting DSM-IV-TR criteria for unipolar MDD, with a Montgomery-Åsberg Depression Rating Scale (MADRS) total score ≥26, presenting with two or three protocol-defined manic symptoms, and who were randomized to 6 weeks of double-blind treatment with either lurasidone 20-60 mg/d (n = 109) or placebo (n = 100). We defined "irritability" as a score ≥2 on both the Young Mania Rating Scale (YMRS) irritability item (#5) and the disruptive-aggressive item (#9). Endpoint change in the MADRS and YMRS items 5 and 9 were analyzed using a mixed model for repeated measures for patients with and without irritability.Results. Some 20.7% of patients met the criteria for irritability. Treatment with lurasidone was associated with a significant week 6 change vs. placebo in MADRS score in both patients with (-22.6 vs. -9.5, p < 0.0001, effect size [ES] = 1.4) and without (-19.9 vs. -13.8, p < 0.0001, ES = 0.7) irritability. In patients with irritable features, treatment with lurasidone was associated with significant week 6 changes vs. placebo in both the YMRS irritability item (-1.4 vs. -0.3, p = 0.0012, ES = 1.0) and the YMRS disruptive-aggressive item (-1.0 vs. -0.3, p = 0.0002, ES = 1.2).Conclusions. In our post-hoc analysis of a randomized, placebo-controlled, 6-week trial, treatment with lurasidone significantly improved depressive symptoms in MDD patients with mixed features including irritability. In addition, irritability symptoms significantly improved in patients treated with lurasidone.

show abstract

Bipolar and Related Disorders

2016

Selecting Effective Treatments

View full text Add to dashboard Cite

Mixed Features in Patients With a Major Depressive Episode

Cited by 150 publications

References 0 publications

Lurasidone for major depressive disorder with mixed features and anxiety: a post-hoc analysis of a randomized, placebo-controlled study

Lurasidone for major depressive disorder with mixed features and anxiety: a post-hoc analysis of a randomized, placebo-controlled study

Lurasidone for major depressive disorder with mixed features and irritability: a post-hoc analysis

Bipolar and Related Disorders

Contact Info

Product

Resources

About